Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25213658 | 0.83 | BACE1 (0.37) | CRHBPCRHR2NT5EESR1ESR2 | |
| SCHEMBL1133977 | 0.80 | NT5E (0.34) | NT5EESR1ESR2HTTCYP2C19 | |
| SCHEMBL11001297 | 0.80 | LMNA (0.46) | NT5ECYP2C19KDM4ELMNACYP1A2 | |
| SCHEMBL25083068 | 0.80 | IMPDH2 (0.42) | ESR1ESR2HTTCYP2C19BACE1 | |
| SCHEMBL14573271 | 0.80 | KDM4E (0.42) | NT5EESR1ESR2HTTCYP2C19 | |
| SCHEMBL1134024 | 0.76 | CYP19A1 (0.40) | — | |
| SCHEMBL3837662 | 0.75 | ACHE (0.40) | CRHBPCRHR2HTTCYP2C19BACE1 | |
| SCHEMBL2011498 | 0.75 | CRHBP (0.39) | CRHBPCRHR2CYP2C19KDM4ECYP3A4 | |
| SCHEMBL24166068 | 0.72 | BACE1 (0.35) | NT5EESR1ESR2HTTCYP2C19 | |
| SCHEMBL10746163 | 0.72 | CYP2C19 (0.39) | NT5EHTTCYP2C19BACE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573907-B | Quinoline derivatives and their use for neurodegenerative diseases | 默克专利有限公司 | 2020-09-08 | — | — | CN | disclosed |
| EP-3152192-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | Merck Patent GmbH (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-20160296509-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160296509-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-20160296509-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-9399623-B2 | Quinoline derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| US-9399623-B2 | Quinoline derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| US-9399623-B2 | Quinoline derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| WO-2015187905-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187905-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | WO | disclosed |
| US-7408065-B2 | P2X7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20080182874-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-07-31 | — | — | US | disclosed |
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| EP-1824838-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2007-08-29 | — | — | EP | disclosed |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| WO-2006059945-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | WO | disclosed |
| EP-1651610-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1633717-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | disclosed |
| WO-2004106305-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182874-A1 | Novel Compounds | REN, F12, GPR119 | CRHBP 2868/4885CRHR2 1076/4885NT5E 2865/4885 |
| US-20160296509-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX7, P2RX3, P2RX1 | CRHBP 3252/4885CRHR2 2998/4885NT5E 128/4885 |
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | NQO2, RECQL, CHRM1 | CRHBP 4223/4885CRHR2 2222/4885NT5E 1433/4885 |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | P2RX7, P2RX1, P2RX2 | CRHBP 3217/4885CRHR2 752/4885NT5E 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.